Advaxis Competitors and Similar CompaniesClear all
Advaxis's competitors and similar companies include Marker Therapeutics and MOLOGEN.
 Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. |  MOLOGEN MOLOGEN AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. | ||
Founding Date | Founding Date 2002 | Founding Date 2018 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Princeton, US HQ | Locations Houston, US HQ | Locations Berlin, DE HQ |
Employees | Employees 3540% decrease | Employees 888% decrease | Employees 4710% decrease |
Valuation ($) | Valuation ($) 2.4 m | Valuation ($) 36.5 m | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) $13k (FY, 2023) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) €81k (FY, 2019) |
Cost of goods | Cost of goods $13k (FY, 2023) | Cost of goods N/A | Cost of goods €2m (FY, 2019) |
Net income | Net income ($48.1m) (FY, 2023) | Net income ($12.2m) (FY, 2025) | Net income (€10.3m) (FY, 2019) |
For sources of this data, please see the company profile
View Company Profiles
Marker Therapeutics
HQ
Houston, US
Employees
8
Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.
View companyMOLOGEN
HQ
Berlin, DE
Employees
47↓ 10% decrease
MOLOGEN AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases.
View company